Natus Medical Incorporated revised revenue guidance for the third quarter of 2016. The company updated its third quarter 2016 revenue guidance to $89 million to $91 million compared to previous guidance of $97 million to $98 million. A majority of the expected shortfall is due to a voluntary ship hold the company placed on certain products produced in its Seattle facility. The remaining shortfall is primarily due to lower demand in the international markets. The ship hold is not related to any product safety issue. The ship hold is in place while the company remediates deficiencies in its engineering and manufacturing quality processes. The company expects to resume shipments of these products during the fourth quarter 2016 and the first quarter of 2017.